An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pittsburgh
With
University of Pittsburgh Medical Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\>/= 18 years old
Enrolled in the UPMC insurance plan for at least 1 year
Identified by UPMC Healthplan as a Pitt/UPMC employee who is likely to benefit from preemptive PGx panel testing based on polypharmacy, high annual prescription costs and a risk for poor medication-related outcomes based on exposure to medications with FDA or CPIC Level A/B PGx guidance using payer data
Participating in Pitt+Me Discovery with elective return of PGx results
You may not be if
Previous panel PGx testing (self-reported)
Have a terminal illness (specifically metastatic cancer, palliative care or hospice)
Have had a liver, small bowel, or allogenic bone marrow/stem cell transplant
Cannot provide informed consent and/or complete the study protocol due to serious cognitive impairment
Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing home facility)
Plan to drop UPMC Health Plan coverage for any reason within 12 months of enrollment
Recent blood transfusion may be exclusionary only if the end of recruitment is nearing and there is insufficient time to observe a minimum waiting period between date of transfusion and date of sample collection. These minimum waiting periods are determined by type of transfusion: 7 days for platelets/plasma/cryoprecipitate; 2 months for packed red blood cells (PRBCs): and 6 months for whole blood or unknown type of transfusion. Although a transfusion is unlikely to have major effects on genotype results from a saliva sample, these time windows remove this concern.
Clareo Health | An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.
